JPRN-jRCT2013210008招募中3 期
A phase3b study of KTE-C19 (at the time of manufacture of commercially available products) in patients with the indication on the package insert
Aso Hiroya0 个研究点目标入组 0 人开始时间: 2021年5月11日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- ot applicable 至 ot applicable（—）
- 性别
- All
入选标准
- •1)Patients who have been identified and manufactured to meet the requirements for treatment with commercially available axicabtagene ciloleucel. The product does not conform to the commercial product specification and cannot be shipped as a commercial product. However, the product conforms to the clinical trial product specification and the sponsor determines that the product can be diverted to the clinical trial product.
- •2)Patients for whom the principal investigator or the subinvestigator has assessed the patient's condition and disease, and determined that they cannot wait for remanufacturing of the product that meets the commercially available specifications from the re-leukocyte apheresis or from the excess PBMC frozen at the manufacturing site.
排除标准
- •Patients for whom the principal investigator or the subinvestigator judged that participation in the clinical trial was inappropriate.
研究者
相似试验
进行中（未招募）
1 期
A Phase II study evaluating efficacy of KTE-X19 CAR-T cell therapy in Relapsed or Refractory Mantle-Cell Lymphoma achieving a partial response during Ibrutinib salvage therapyRelapsed or Refractory Mantle-Cell LymphomaMedDRA version: 21.1Level: PTClassification code: 10026801Term: Mantle cell lymphoma refractory Class: 100000004864MedDRA version: 20.0Level: PTClassification code: 10061275Term: Mantle cell lymphoma Class: 100000004864MedDRA version: 21.0Level: PTClassification code: 10026800Term: Mantle cell lymphoma recurrent Class: 100000004864CTIS2022-502907-31-00Fondazione IRCCS Istituto Nazionale Dei Tumori20
进行中（未招募）
3 期
A clinical study of KLH-2109 in uterine fibroids patient with menorrhagia and paiterine fibroidJPRN-jRCT2031220181Shimizu Yoshitaka78
进行中（未招募）
3 期
A clinical study of KLH-2109 in uterine fibroids patient with menorrhagiaterine fibroidJPRN-jRCT2031220180Shimizu Yoshitaka264
已完成
3 期
K-924-03HypercholesterolemiaJPRN-jRCT2080225088Kowa Company, Ltd.110
进行中（未招募）
1 期
Effect of CT1812 Treatment on Aß Oligomer Displacement into CSFSponsor is developing an oral formulation of CT1812 fumarate to treat AD and mild cognitive impairment.MedDRA version: 20.0Level: LLTClassification code 10001896Term: Alzheimer's diseaseSystem Organ Class: 100000004852EUCTR2018-000163-89-SECognition Therapeutics, Inc.18